RT Journal Article
SR Electronic
T1 The controversy over long-acting beta agonists: Examining the evidence
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 973
OP 992
VO 73
IS 11
A1 David M. Lang
YR 2006
UL http://www.ccjm.org/content/73/11/973.abstract
AB In the Salmeterol Multicenter Asthma Research Trial (SMART), patients receiving the long-acting beta agonist salmeterol—particularly African Americans—had a statistically significantly higher risk of fatal or potentially fatal asthma episodes. As a result, medications that contain salmeterol (Serevent, Advair) or formoterol (Foradil) carry a “black box warning.” However, the benefits of these drugs continue to outweigh the risks, if they are used appropriately.